Drug Profile
ASP 6294
Alternative Names: ASP-6294Latest Information Update: 01 Oct 2021
Price :
$50
*
At a glance
- Originator Astellas Pharma
- Class Antibodies; Urologics
- Mechanism of Action Nerve growth factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Interstitial cystitis
Most Recent Events
- 21 Mar 2019 Astellas Pharma completes the phase II SERENITY trial in Interstitial cystitis in Belgium, Czech Republic, Germany, Hungary, Latvia, Netherlands, Poland, Russia, Spain, United Kingdom (SC) (NCT03282318; EudraCT2016-004138-12)
- 28 Feb 2019 No recent reports of development identified for phase-I development in Interstitial-cystitis(In volunteers) in United Kingdom (IV, Injection)
- 28 Feb 2019 No recent reports of development identified for phase-I development in Interstitial-cystitis(In volunteers) in United Kingdom (SC, Injection)